longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Impact BioMedical

IBO

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 5.70, above the reasonable range, cheaper than 11.88% of the time in the past 1 years, and the industry ranks 56/257, the industry Median -1.46.

5.7xP/E
$0.53Stock price
$0.09Earnings per share
5.7xP/E
Stock price$0.53Earnings per share$0.09

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-1.20x
Typical range
-4.56x–-0.20x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0306090120

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
NVOUSNovo Nordisk AS
9.63x6.47%$174.26B
SGIOYUSShionogi
9.50x--$16.00B
INVAUSInnoviva
4.24x34.79%$1.52B
APMDUSApnimed
6.21x114.94%$1.02B
CRMDUSCormedix
3.26x75.74%$606.41M
ORMPUSOramed Pharma
1.14x198.00%$197.59M
OGIUSOrganigram
2.41x510.33%$149.86M
SDEVUSStablecoin Development
0.13x--$64.28M
IBOUSImpact BioMedical
5.70x--$4.51M
BTMDUSbiote Corp.
8.10x127.70%$47.42M
OWPCUSOne World Products, Inc.
0.04x--$142.42K

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.